Abstract
Background Spain has been disproportionately affected by the COVID-19 pandemic with the second highest death toll in the world after Italy. Here we analyzed estimates of pandemic severity and investigated how different factors shaped the severity of the COVID-19 pandemic.
Methods We retrieved the daily cumulative numbers of laboratory-confirmed COVID-19 cases and deaths in Spain from February 20, 2020 to April 2, 2020. We used statistical methods to estimate the time-delay adjusted case fatality ratio (CFR) for 17 autonomous areas and 2 autonomous cities of Spain. We then assessed how transmission and sociodemographic variables were associated with the CFR across areas in Spain using multivariate regression analysis.
Results We estimated the highest time-delay-adjusted CFR for Madrid (38.4%) and the average adjusted CFR in Spain at 23.9%. Our multivariate regression analysis revealed a statistically significant three predictor variables: infant mortality rate, poverty risk rate and the cumulative morbidity rate.
Conclusions Our estimates of the time-delay adjusted CFR for 12 autonomous areas/cities in Spain are significantly higher than those previously estimated for other geographic regions including China and Korea. Our results call for urgent public health interventions focusing on low socioeconomic groups to ameliorate the burden of the COVID-19 pandemic in Spain.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KM acknowledges support from the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 15K20936, and from the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture, Sport, Science & Technology of Japan. GC acknowledges support from NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program; UK Biotechnology and Biological Sciences Research Council grant BB/M008894/1.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.